公开(公告)号：US08114874B2

公开(公告)日：2012-02-14

申请号：US11644849

申请日：2006-12-22

申请人： Dong Zou ,  Wei-Sheng Huang ,  R. Mathew Thomas ,  Jan Antionette C. Romero ,  Jiwei Qi ,  Yihan Wang ,  Xiaotian Zhu ,  William C. Shakespeare ,  Rajeswari Sundaramoorthi ,  Chester A. Metcalf, III ,  David C. Dalgarno ,  Tomi K. Sawyer

发明人： Dong Zou ,  Wei-Sheng Huang ,  R. Mathew Thomas ,  Jan Antionette C. Romero ,  Jiwei Qi ,  Yihan Wang ,  Xiaotian Zhu ,  William C. Shakespeare ,  Rajeswari Sundaramoorthi ,  Chester A. Metcalf, III ,  David C. Dalgarno ,  Tomi K. Sawyer

IPC分类号： A61K31/495

CPC分类号： C07D471/04 ,  C07D473/34 ,  C07D487/04

摘要： This invention relates to compounds of the general formula: in which the variable groups are as defined herein, and to their preparation and use. In particular, the compounds include embodiments in which Ring T is an imidazo[1,2-b]pyridazine ring system, Rings A and B are each aryl and L1 is —C(O)NR1— or —NR1C(O)—. Uses for the compounds and for compositions containing them include treatment of cancer and other diseases mediated by protein kinases.

摘要翻译： 本发明涉及以下通式的化合物：其中可变基团如本文所定义，及其制备和用途。 特别地，化合物包括其中环T是咪唑并[1,2-b]哒嗪环体系的实施方案，环A和B各自为芳基且L 1为-C（O）NR 1 - 或-NR 1 C（O） - 。 用于化合物和含有它们的组合物的用途包括治疗由蛋白激酶介导的癌症和其它疾病。

公开(公告)号：US20120135986A1

公开(公告)日：2012-05-31

申请号：US13357745

申请日：2012-01-25

申请人： Dong Zou ,  Wei-Sheng Huang ,  R. Mathew Thomas ,  Jan Antionette C. Romero ,  Jiwei Qi ,  Yihan Wang ,  Xiaotian Zhu ,  William C. Shakespeare ,  Rajeswari Sundaramoorthi ,  Chester A. Metcalf, III ,  David C. Dalgarno ,  Tomi K. Sawyer

发明人： Dong Zou ,  Wei-Sheng Huang ,  R. Mathew Thomas ,  Jan Antionette C. Romero ,  Jiwei Qi ,  Yihan Wang ,  Xiaotian Zhu ,  William C. Shakespeare ,  Rajeswari Sundaramoorthi ,  Chester A. Metcalf, III ,  David C. Dalgarno ,  Tomi K. Sawyer

IPC分类号： A61K31/5377 ,  A61K31/4985 ,  C07D471/04 ,  A61K31/437 ,  A61P35/00 ,  A61K31/5025 ,  A61K31/53 ,  A61K31/519 ,  C07D473/34 ,  A61K31/52 ,  C07D487/04 ,  A61K31/496

CPC分类号： C07D471/04 ,  C07D473/34 ,  C07D487/04

摘要： This invention relates to compounds of the general formula: in which the variable groups are as defined herein, and to their preparation and use.

摘要翻译： 本发明涉及以下通式的化合物：其中可变基团如本文所定义，以及其制备和用途。

公开(公告)号：US20170216295A1

公开(公告)日：2017-08-03

申请号：US15501103

申请日：2015-07-27

申请人： Bhuamik Pandya ,  Blaise Lippa ,  Xin Zhang ,  Jon Christian Baber ,  Jan Antionette C. Romero ,  Jing Zhang

发明人： Bhuamik Pandya ,  Blaise Lippa ,  Xin Zhang ,  Jon Christian Baber ,  Jan Antionette C. Romero ,  Jing Zhang

IPC分类号： A61K31/519 ,  C07D487/04

CPC分类号： A61K31/519 ,  C07D487/04

摘要： Provided herein are compounds that inhibit CCR9 receptor function. Also provided herein are methods of treating inflammatory disease in a subject, comprising administering to the subject a compound of the invention. Accordingly, in one aspect, provided herein is a compound of Formula (1) or a pharmaceutically acceptable salt thereof. In another aspect, provided herein is a pharmaceutical composition, comprising a compound of Formula (1), and a pharmaceutically acceptable carrier.